Logo image of PYPD

POLYPID LTD (PYPD) Stock Fundamental Analysis

NASDAQ:PYPD - Nasdaq - IL0011326795 - Common Stock - Currency: USD

3.05  -0.09 (-2.87%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to PYPD. PYPD was compared to 195 industry peers in the Pharmaceuticals industry. PYPD may be in some trouble as it scores bad on both profitability and health. PYPD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PYPD had negative earnings in the past year.
In the past year PYPD has reported a negative cash flow from operations.
In the past 5 years PYPD always reported negative net income.
In the past 5 years PYPD always reported negative operating cash flow.
PYPD Yearly Net Income VS EBIT VS OCF VS FCFPYPD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

PYPD has a worse Return On Assets (-115.08%) than 77.44% of its industry peers.
PYPD's Return On Equity of -377.69% is on the low side compared to the rest of the industry. PYPD is outperformed by 76.92% of its industry peers.
Industry RankSector Rank
ROA -115.08%
ROE -377.69%
ROIC N/A
ROA(3y)-134.62%
ROA(5y)-95.15%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PYPD Yearly ROA, ROE, ROICPYPD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K

1.3 Margins

PYPD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYPD Yearly Profit, Operating, Gross MarginsPYPD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, PYPD has more shares outstanding
The number of shares outstanding for PYPD has been increased compared to 5 years ago.
The debt/assets ratio for PYPD has been reduced compared to a year ago.
PYPD Yearly Shares OutstandingPYPD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
PYPD Yearly Total Debt VS Total AssetsPYPD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

PYPD has an Altman-Z score of -17.23. This is a bad value and indicates that PYPD is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PYPD (-17.23) is worse than 78.46% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that PYPD is not too dependend on debt financing.
PYPD has a Debt to Equity ratio (0.08) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -17.23
ROIC/WACCN/A
WACCN/A
PYPD Yearly LT Debt VS Equity VS FCFPYPD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

PYPD has a Current Ratio of 1.31. This is a normal value and indicates that PYPD is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.31, PYPD is doing worse than 75.90% of the companies in the same industry.
PYPD has a Quick Ratio of 1.31. This is a normal value and indicates that PYPD is financially healthy and should not expect problems in meeting its short term obligations.
PYPD has a Quick ratio of 1.31. This is in the lower half of the industry: PYPD underperforms 67.18% of its industry peers.
Industry RankSector Rank
Current Ratio 1.31
Quick Ratio 1.31
PYPD Yearly Current Assets VS Current LiabilitesPYPD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

PYPD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.30%, which is quite impressive.
EPS 1Y (TTM)66.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PYPD will show a very strong growth in Earnings Per Share. The EPS will grow by 22.64% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y61.79%
EPS Next 2Y32.7%
EPS Next 3Y31.38%
EPS Next 5Y22.64%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PYPD Yearly Revenue VS EstimatesPYPD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 200M 400M 600M
PYPD Yearly EPS VS EstimatesPYPD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PYPD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PYPD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYPD Price Earnings VS Forward Price EarningsPYPD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYPD Per share dataPYPD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

PYPD's earnings are expected to grow with 31.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.7%
EPS Next 3Y31.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PYPD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

POLYPID LTD

NASDAQ:PYPD (6/4/2025, 11:31:01 AM)

3.05

-0.09 (-2.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners163.87%
Inst Owner Change-95.08%
Ins Owners52.09%
Ins Owner ChangeN/A
Market Cap31.08M
Analysts82.22
Price Target11.56 (279.02%)
Short Float %0.53%
Short Ratio1.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.66%
Min EPS beat(2)-21.92%
Max EPS beat(2)-19.4%
EPS beat(4)2
Avg EPS beat(4)-7.69%
Min EPS beat(4)-21.92%
Max EPS beat(4)5.63%
EPS beat(8)4
Avg EPS beat(8)4.15%
EPS beat(12)8
Avg EPS beat(12)6.4%
EPS beat(16)10
Avg EPS beat(16)4.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.13%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.04
P/tB 4.04
EV/EBITDA N/A
EPS(TTM)-4.26
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS0
BVpS0.75
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.08%
ROE -377.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-134.62%
ROA(5y)-95.15%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.31
Quick Ratio 1.31
Altman-Z -17.23
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)116.76%
Cap/Depr(5y)104.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.91%
EPS Next Y61.79%
EPS Next 2Y32.7%
EPS Next 3Y31.38%
EPS Next 5Y22.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.8%
EBIT Next 3Y12.14%
EBIT Next 5YN/A
FCF growth 1Y51.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.78%
OCF growth 3YN/A
OCF growth 5YN/A